Changes in Intraocular Pressure After Intravitreal Injection

Intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections introduce additional fluid volume into the eye, which can cause an acute, transient elevation in intraocular pressure (IOP). The purpose of this prospective observational study is to evaluate the immediate and early changes in intraocular pressure following intravitreal anti-VEGF injections and to determine how rapidly pressure recovers toward baseline levels.

Adult participants scheduled to receive routine intravitreal anti-VEGF therapy for established clinical indications, such as diabetic macular edema, neovascular age-related macular degeneration, or retinal vein occlusion, will be enrolled. Intraocular pressure will be measured using an Icare rebound tonometer with single-use disposable probes before injection (baseline) and at 1 minute, 5 minutes, and 20 minutes post-injection. The study will also analyze whether factors such as refractive error, the number of prior injections, or the type of anti-VEGF drug administered affect the severity of post-injection pressure spikes and subsequent recovery.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Diabetic Macular Edema Cardiovascular Diseases Embolism and Thrombosis Eye Diseases Neovascular Age-related Macular Degeneration Ocular Hypertension Retinal Diseases Retinal Vein Occlusion Thrombosis Vascular Diseases Venous Thrombosis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age 18 years or older.
Scheduled to receive an intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection for an established clinical indication (e.g., diabetic macular edema, neovascular age-related macular degeneration, or retinal vein occlusion).
Provision of written informed consent prior to enrollment.

Exclusion criteria

Known history of glaucoma or ocular hypertension.
History of previous glaucoma surgery.
Corneal diseases or ocular conditions that significantly interfere with accurate intraocular pressure measurement.
Inability to cooperate adequately during intraocular pressure measurement.
Refusal to participate or failure to provide informed consent.
Development of marked intraocular pressure elevation immediately after injection (IOP ≥ 40 mmHg) requiring anterior chamber paracentesis.

Treatment and study plan

Primary outcomes

Change from Baseline in Intraocular Pressure at 1 Minute

Time frame: Baseline and 1 minute post-injection

Intraocular pressure will be measured in mmHg using an Icare rebound tonometer with a single-use disposable probe to assess the acute post-injection pressure spike compared to baseline.
Change from Baseline in Intraocular Pressure at 5 Minutes

Time frame: Baseline and 5 minutes post-injection

Intraocular pressure will be measured in mmHg using an Icare rebound tonometer with a single-use disposable probe to evaluate early post-injection pressure trends.
Change from Baseline in Intraocular Pressure at 20 Minutes

Time frame: Baseline and 20 minutes post-injection

Intraocular pressure will be measured in mmHg using an Icare rebound tonometer to assess the rate and extent of pressure recovery toward pre-injection baseline levels.

Sponsors and collaborators

Lead sponsor

Assiut University

Other

Registry information

Official study title

Monitoring Changes in Intraocular Pressure After Intravitreal Injection

Important dates

Study start: 2026
Primary completion: 2027
Study completion: 2027
First posted: Sep 17, 2026
Registry last updated: Sep 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, not recruiting